MC4R-Selective VHH Polypeptides for Reduced Off-Target Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current MC4R agonists lack receptor selectivity, leading to undesired side effects due to off-target activation of other melanocortin receptors, necessitating the development of more specific MC4R agonists for therapeutic interventions like anti-obesity treatments.
Innovation Solution
Development of amino acid sequences and polypeptides that specifically bind to MC4R with high affinity, reducing off-target effects by enhancing selectivity and targeting the MC4R receptor.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current MC4R agonists are used for therapeutic intervention, then MC4R activation is achieved, but off-target activation of other melanocortin receptors occurs causing undesired side effects
Solution Approach 1:
The patent applies local quality by designing polypeptides with specific amino acid sequences that are tailored to interact with unique structural features of the MC4R receptor. The polypeptides contain precisely engineered binding interfaces that recognize specific epitopes on MC4R, allowing selective activation of this receptor subtype while avoiding cross-reactivity with other melanocortin receptors (MC1R, MC2R, MC3R, MC5R). This localized molecular recognition ensures high receptor selectivity and eliminates off-target side effects.
2Object-affected harmful factors
If polypeptides with high MC4R specificity are developed, then off-target effects are reduced, but development complexity and time increase
Solution Approach 1:
The patent employs segmentation by dividing the polypeptide structure into distinct functional domains: an N-terminal region, a central variable region containing the MC4R-specific binding epitope, and a C-terminal region. This modular design allows researchers to focus on optimizing the central variable region for MC4R specificity while keeping the terminal regions standardized. The segmented approach simplifies the design process by breaking down the complex requirement for specificity into manageable structural components.
Solution Approach 2:
The patent applies universality by designing polypeptides that can be produced using standardized expression systems and purification protocols. The polypeptide backbone incorporates universal features such as signal peptides for secretion, standardized linkers, and purification tags that are compatible with common biomanufacturing platforms. This universal design framework reduces development complexity by allowing the use of established protocols while the variable central region provides the required MC4R specificity.
Data Source
AI summary
The present invention relates to agonist VHH that are specific for (as defined herein) melanocortin 4 receptor (“MC4R”), as well as to proteins and polypeptides, that comprise or essentially consist of one or more such VHH sequences and medical uses to reduce body weight.